Methods of preventing or treating Parkinson's disease in subjects are described where drugs are administered to subjects in effective amounts to cause the farnesylation of PARIS and the enhanced expression of PGC-1α in the brain. These methods alleviate the effects of Parkinson's disease in subjects, in part, by preventing the loss of dopamine neurons.

Methods of preventing or treating Parkinson's disease in subjects are described where drugs are administered to subjects in effective amounts to cause the farnesylation of PARIS and the enhanced expression of PGC-1α in the brain. These methods alleviate the effects of Parkinson's disease in subjects, in part, by preventing the loss of dopamine neurons.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

The present invention provides for a method for the treatment of a respiratory disease, disorder or condition, or a viral infection or viral disease, disorder or condition in a subject, the method comprising the step of administering to said subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises niclosamide or a pharmaceutically acceptable salt thereof and wherein the medically active liquid is administered in nebulized form using an inhalation device.

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of therapeutic agents to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of therapeutic agents to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

The disclosure relates to compositions, methods, and kits for using perillyl alcohol and/or an Argonaute protein (e.g., Ago-2) to deliver a polynucleotide to a cell. The disclosure also relates to compositions, methods, and kits for treating a condition by using perillyl alcohol and/or an Argonaute protein (e.g., Ago-2) to deliver a polynucleotide to a cell. The conditions may be brain vascular diseases and brain tumors.

The disclosure relates to compositions, methods, and kits for using perillyl alcohol and/or an Argonaute protein (e.g., Ago-2) to deliver a polynucleotide to a cell. The disclosure also relates to compositions, methods, and kits for treating a condition by using perillyl alcohol and/or an Argonaute protein (e.g., Ago-2) to deliver a polynucleotide to a cell. The conditions may be brain vascular diseases and brain tumors.